Bon Opus Biosciences

Executive Summary

Bon Opus Biosciences is a San Diego-based private company founded in 2020 that provides high-quality recombinant proteins, recombinant antibodies, and peptide synthesis services to the scientific and academic communities. By combining technical expertise with a customer-centric approach, the company enables researchers to accelerate their discoveries through reliable, custom reagents. As a contract research organization (CRO) and reagent supplier, Bon Opus focuses on consistency and reproducibility, which are critical for drug development and basic research. The company operates in a competitive landscape but differentiates itself through dedicated partnership and quality assurance. With no disclosed funding rounds or pipeline, Bon Opus appears to be a small, bootstrapped entity focused on service revenue. Its growth potential lies in expanding its client base, forming strategic collaborations, and scaling manufacturing capabilities. Given the steady demand for research reagents and outsourcing trends, Bon Opus is well-positioned to grow organically, though its private nature limits visibility into financial or operational milestones.

Upcoming Catalysts (preview)

• TBDMajor pharmaceutical or biotech partnership for custom antibody services40% success
• TBDLaunch of a new high-demand product line, e.g., CRISPR-associated proteins35% success
• Q3 2026Series A funding round to scale production capacity30% success